- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- Sandoz to market authorized generic version of Adderall XR
- CareMed selected to distribute Tarceva
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
PRINCETON, N.J. — The Food and Drug Administration has approved and launched two generic contraceptives made by Sandoz, the drug maker said.
Sandoz, the generics division of Swiss drug maker Novartis, announced the approval of Estarylla (norgestimate and ethinyl estradiol tablets) and Tri-Estarylla (norgestimate and ethinyl estradiol tablets), generic versions of Johnson & Johnson's Ortho Cyclen and Ortho Tri-Cyclen, respectively. Sandoz said the launches brought the total number of oral contraceptives it has launched since the beginning of 2011 to six.
"We are pleased to add two more products to our portfolio of oral contraceptives," Sandoz president Don DeGolyer said. "Sandoz is committed to helping meet the needs of women in the U.S. by providing cost-saving, high-quality options for women's healthcare."
Ortho Cyclen and Ortho Tri-Cyclen had sales of $116 million and $240 million, respectively, during the 12-month period that ended in January 2013.